Exclusion criteria, especially use of GLP‐1 analogues and insulin, and proliferative retinopathy, may have led to selection of participants with longstanding diabetes with lean phenotype, an acceptable HbA1c and overall few microvascular complications. The gene discussed is GLP1R; the disease is retinal disorder.